Indications: Leber Hereditary Optic Neuropathy (LHON)
The leading causes of vision impairment and blindness are posterior segment-related diseases including Leber Hereditary Optic Neuropathy (LHON), age-related macular degeneration, diabetic macular edema, glaucoma, endophthalmitis etc. However, blood-ocular barriers, like blood-brain barrier, refrain most of therapeutic drugs from being transported into the eye, especially to the posterior-segment of eye. For overcoming the barriers, the characteristics of MSN such as the nanoparticle size, surface charge, and constitution, etc., can be modulated to increase penetration of static and dynamic barriers of eyes, thereby improving ocular bioavailability.
Drugs@MSN solution is clear, transparent, and homogeneous, that will be a potential nano-formulation for eye drug delivery and the administration route could be intravitreal administration or eye drop.